GPR120 suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy

Abstract

GPR40 and GPR120 are fatty acid sensors that play important roles in glucose and energy homeostasis. GPR40 potentiates glucose-dependent insulin secretion and demonstrated in clinical studies robust glucose lowering in type 2 diabetes. GPR120 improves insulin sensitivity in rodents, albeit its mechanism of action is not fully understood. Here, we postulated that the antidiabetic efficacy of GPR40 could be enhanced by coactivating GPR120. A combination of GPR40 and GPR120 agonists in db/db mice, as well as a single molecule with dual agonist activities, achieved superior glycemic control compared with either monotherapy. Compared with a GPR40 selective agonist, the dual agonist improved insulin sensitivity in ob/ob mice measured by hyperinsulinemic-euglycemic clamp, preserved islet morphology, and increased expression of several key lipolytic genes in adipose tissue of Zucker diabetic fatty rats. Novel insights into the mechanism of action for GPR120 were obtained. Selective GPR120 activation suppressed lipolysis in primary white adipocytes, although this effect was attenuated in adipocytes from obese rats and obese rhesus, and sensitized the antilipolytic effect of insulin in rat and rhesus primary adipocytes. In conclusion, GPR120 agonism enhances insulin action in adipose tissue and yields a synergistic efficacy when combined with GPR40 agonism. GPR40 and GPR120 are fatty acid sensors that play important roles in glucose and energy homeostasis. GPR40 potentiates glucose-dependent insulin secretion and demonstrated in clinical studies robust glucose lowering in type 2 diabetes. GPR120 improves insulin sensitivity in rodents, albeit its mechanism of action is not fully understood. Here, we postulated that the antidiabetic efficacy of GPR40 could be enhanced by coactivating GPR120. A combination of GPR40 and GPR120 agonists in db/db mice, as well as a single molecule with dual agonist activities, achieved superior glycemic control compared with either monotherapy. Compared with a GPR40 selective agonist, the dual agonist improved insulin sensitivity in ob/ob mice measured by hyperinsulinemic-euglycemic clamp, preserved islet morphology, and increased expression of several key lipolytic genes in adipose tissue of Zucker diabetic fatty rats. Novel insights into the mechanism of action for GPR120 were obtained. Selective GPR120 activation suppressed lipolysis in primary white adipocytes, although this effect was attenuated in adipocytes from obese rats and obese rhesus, and sensitized the antilipolytic effect of insulin in rat and rhesus primary adipocytes. In conclusion, GPR120 agonism enhances insulin action in adipose tissue and yields a synergistic efficacy when combined with GPR40 agonism. Type 2 diabetes mellitus (T2DM) represents a global health threat, and it is well recognized that insulin resistance and β-cell failure are core metabolic impairments in the pathobiology of T2DM. Discovery of novel pharmacological approaches to alleviate insulin resistance has pro­ven especially challenging. Thiazolidinediones (TZDs) are generally acknowledged as the only class of antidiabetic drugs that work directly as insulin sensitizers in the clinic. However, adverse effects such as edema, weight gain, and increased cardiovascular and bone fracture risk have limited the use of this class of drugs in the treatment of T2DM (1.Ciudin A. Hernandez C. Simo R. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.Curr. Top. Med. Chem. 2012; 12: 585-604Crossref PubMed Scopus (28) Google Scholar). GPR40 and GPR120 have each emerged as a potential target for T2DM in recent years (2.Ichimura A. fatty acid as for the treatment of PubMed Scopus Google and by agonists for improved glucose PubMed Scopus Google Scholar). are fatty that play important roles in glucose and energy homeostasis. GPR120 is in adipocytes, and A. C. and of expression of the fatty acid PubMed Scopus Google and its activation was to insulin in obese mice R. agonist improves insulin resistance and in obese Med. PubMed Scopus Google Scholar). has postulated that mechanism by GPR120 improves insulin resistance is of in adipose tissue that in a of R. agonist improves insulin resistance and in obese Med. PubMed Scopus Google GPR120 is fatty acid and PubMed Scopus Google Scholar). fatty acid of fatty were to GPR120 to glucose in adipocytes of a class of with and PubMed Scopus Google Scholar). of GPR120 to be A was in GPR120 that the and this was to the risk of in A. A. A. A. of GPR120 to in and 2012; PubMed Scopus Google although a with risk for T2DM was not A. A. A. R. C. of the in to increased glucose Med. PubMed Scopus Google Scholar). the was to although it was not with increased risk of glucose in a that was C. A. C. and of the in the Med. PubMed Scopus Google Scholar). of the of the was to the by GPR120 activation insulin sensitivity and glucose homeostasis. GPR40 is and in A. C. R. agonists of glucose-dependent insulin secretion and glucose in PubMed Scopus Google Scholar). of GPR40 potentiates glucose-dependent insulin lowering glucose and in in of diabetes A. C. R. agonists of glucose-dependent insulin secretion and glucose in PubMed Scopus Google effects of a selective fatty acid agonist, on insulin and secretion in rat and 2012; PubMed Scopus Google Scholar). of GPR40 has demonstrated as a molecule agonist achieved glucose lowering with risk of in 2 and clinical in T2DM R. R. and safety of a agonist, in with type 2 diabetes by and a PubMed Scopus Google R. R. safety and efficacy of a agonist, as and combination in with type 2 a PubMed Scopus Google Scholar). of this was to the of R. R. and safety of a agonist, in with type 2 diabetes by and a PubMed Scopus Google of the was to the GPR40 mechanism of GPR40 be as a target for glucose lowering in T2DM. GPR40 agonists such as and in to the fatty acid and agonists such as the and robust secretion and efficacy in combined and in is with robust action and in PubMed Scopus Google Scholar). treatment with agonists to superior clinical is to be and fatty to be the for GPR40 and although the fatty acid in the PubMed Scopus Google Scholar). has in the that it is to dual agonist for GPR40 and GPR120 of fatty on and and of acid as a dual agonist with potential effect metabolic PubMed Scopus Google Scholar). In the we postulated that to the antidiabetic efficacy of GPR40 be to target GPR40 and insulin and insulin this by and treatment in several diabetic with a combination of a GPR40 agonist and a GPR120 agonist, with a dual agonist, a GPR40 selective In we the mechanism of action insulin and was on studies that lipolysis in adipocytes. GPR40 selective agonists combined and in is with robust action and in PubMed Scopus Google and the GPR120 selective agonists A R. agonist improves insulin resistance and in obese Med. PubMed Scopus Google and and of the of PubMed Scopus Google and the GPR40 and GPR120 dual agonist R. and of the agonist of of on in in were by and were by was from was from for and treatment of primary adipocytes was of and with fatty of the for were from GPR40 rat GPR40 were in with and was with were in and were by the as C. and of novel and selective Med. Chem. PubMed Scopus Google Scholar). GPR120 and rat GPR120 was with the as C. and of novel and selective Med. Chem. PubMed Scopus Google Scholar). was by and rat GPR120 2 were as C. and of novel and selective Med. Chem. PubMed Scopus Google Scholar). of GPR120 was by of in the to were with and in and a of for GPR120 for rat GPR120 in were in from 2 and of the was to each well of a white in the was was in a of and was to each well of the in the was of the was to each well of the and the were for for rat was as the and was to each were the the were in a with a for dual and each a of was the were to a of by the and the each of was by activation in that and was in that and a of a GPR120 agonist to the were in a by and were by the db/db mice were mice and with and the db/db mice were on and weight into treatment and the were for GPR40 agonist GPR120 agonist A of and A and for each was in and the adverse effects were glucose were measured and weight was on and mice were the of for of the mice of and glucose were measured by a and and insulin db/db mice were and to glucose and and a of mice treatment was as a were in for and the treatment GPR40 agonist GPR120 agonist A combination of and A and dual agonist and glucose were measured glucose and insulin were measured on glucose was on with in the from the of the of of of weight was by glucose were from by a and and glucose insulin were measured by the and were measured by the and the ob/ob mice on the were for into and with the a GPR40 agonist a dual agonist for and insulin were measured of the mice were with and and to for mice with weight were from the sensitivity was by a hyperinsulinemic-euglycemic as C. in Google Scholar). on the of the mice were for and mice were a of and were and to glucose the was by of insulin glucose were measured and by of with were the to glucose and glucose a of glucose was to glucose glucose were and mice were and were and insulin sensitivity was by glucose the by the insulin the of the were by and with to of were in with with a and for and to for was as the was to the of on the were by of glucose were by each with A. of glucose in PubMed Scopus Google Scholar). were and in a acid in as to of tissue of was and were from by were by with and were in a Zucker diabetic fatty rats and and control Zucker rats were of from the rats were a from and from for to Zucker diabetic fatty rats and in the of PubMed Scopus Google Scholar). rats were a treatment in rats of the was to were treatment with GPR40 agonist of weight and dual agonist were a and the treatment for was on were for by of of weight of glucose were from by a and and glucose and insulin were measured by the tissue was were was and in for in and of tissue each and were to insulin and by primary were in this and were by of and the were with a glucose for and with the for were with was by the were by a and the and by was to in was to the by to the of and in each insulin were to be and with were as rats were of from the rats were on weight and were were from and and of either a GPR120 agonist and insulin were measured with the from the and from and the and for genes were from expression were by the from was as the control to the of each in expression for the adipose tissue from the rat was by as expression in from and with of in PubMed Scopus Google Scholar). was by the to the were on by a and expression was in were to the rat by the with a of were by the as in and of to the rat to expression was by the as in with the from the as adipocytes were from white adipose tissue as C. for lipolysis in primary PubMed Scopus Google Scholar). the from a rat were and with were and in in a were into a with with fatty with type of adipose and with for was a into a and to for the was by a and of adipocytes was with of with fatty adipocytes were into of with glucose and of the to a of adipocytes, was to each well of a treatment as in and was for of was into a to the by and from by the from were from a of rhesus that were either the were on a were with and with was A was in the of the to the on and a of was adipose tissue were and in primary adipocytes were a as the that type was in the adipose tissue was from was a with of are as was by either by in as was as the efficacy of a combination of GPR40 and GPR120 either db/db mice were for with a GPR40 selective agonist combined and in is with robust action and in PubMed Scopus Google a GPR120 selective agonist A R. agonist improves insulin resistance and in obese Med. PubMed Scopus Google the of were R. agonist improves insulin resistance and in obese Med. PubMed Scopus Google combined and in is with robust action and in PubMed Scopus Google and and are in the that was for each was in studies as the treatment was in the as a A was for studies in mice it has a in is for the glucose was with treatment increased of the a effect on weight compared with with the GPR40 agonist in a of as on although the effect to from treatment treatment with the GPR120 agonist A for glucose lowering on this efficacy was not In to either the of GPR40 and GPR120 agonists a lowering of glucose insulin of was improved by the combination and by not by either GPR40 agonist GPR120 agonist as of are the of not in a of in in a of in in a are the of not the metabolic of combination of GPR40 and GPR120 in a in db/db mice, and as compared with and as were in db/db mice, this and the of the a effect on weight compared with the the of the GPR40 selective agonist a robust effect to of the effect was not the and of the GPR120 selective agonist A not a effect to the of combination of GPR40 and GPR120 agonists of the treatment this a single molecule with and dual agonist the of with efficacy to that of and the GPR40 agonist the GPR120 agonist as glucose were in the for GPR120 agonist insulin were in the GPR120 and dual agonist that GPR120 activation improved insulin sensitivity glucose measured of treatment was improved by with the dual agonist the were increased in the db/db mice compared with and mice dual agonist treatment a effect to in the and In a of diabetes that a dual agonist for GPR40 and GPR120 efficacy to a combination of selective in glycemic control and superior to either as monotherapy. the dual agonist a robust effect to the GPR120 selective agonist A was to insulin sensitivity in mice, a of insulin resistance with R. agonist improves insulin resistance and in obese Med. PubMed Scopus Google Scholar). activation of GPR120 and GPR40 by a dual agonist insulin sensitivity in a diabetic that and we compared treatment with a dual agonist a GPR40 selective agonist in ob/ob and have in in was as a control for insulin treatment with effect on weight when compared with mice the treatment was in compared with glucose measured on of treatment with and was in the and and the and when compared with mice and in a and and for as compared with mice sensitivity was by hyperinsulinemic-euglycemic of glucose are in with treatment increased the the clamp, by compared with mice, and improved of glucose and the glucose as in was increased by the dual agonist not by the GPR40 selective agonist that the in insulin sensitivity of the dual agonist is by GPR120 insulin sensitivity was and in was a in the of insulin to not to by the dual agonist that increased insulin sensitivity in the by the dual agonist the key of improved insulin the pharmacological effects on tissue insulin was measured in the of the treatment increased glucose in when compared with mice However, the GPR40 selective agonist the dual agonist glucose in of lipolysis is a key metabolic of insulin sensitivity in adipose potential treatment effects on adipose we and and hyperinsulinemic-euglycemic treatment with in and However, the GPR40 selective agonist the dual agonist a effect on of and of the clamp, was suppressed by and by in mice, adipose tissue insulin resistance in ob/ob mice by clamp, with its effect to insulin action treatment with and by and although was compared with of the a to in of the of glucose of into and of and it that the of insulin sensitivity by a dual agonist is by improved insulin action in the the dual agonist treatment have metabolic in a we compared treatment of the dual agonist with the GPR40 selective agonist in diabetic a of with and rats were on a and to and Zucker diabetic fatty rats and in the of PubMed Scopus Google Scholar). were and treatment was the of the and have in rat GPR40 and treatment were in this the GPR40 selective agonist the dual agonist and a control in the treatment with effect on weight compared with the not with either to in the of the the dual agonist achieved a of and this was by a for insulin of the GPR40 selective agonist and the dual agonist glucose by the the in glucose the of glucose was for the GPR40 agonist and the In the of the glucose was by the dual agonist treatment in a glucose the with the selective GPR40 agonist and insulin were GPR40 agonist with effect as insulin insulin was the dual agonist and insulin in to glucose increased and to in the dual agonist treatment the improved glucose of β-cell in the dual rats. of the of the and a insulin in of the rats compared with Zucker control rats of from dual rats not from selective GPR40 rats a of islet and a of of was not by either treatment in the ob/ob that dual agonism to of insulin postulated that this effect be to GPR120 agonism GPR40 agonism not a metabolic However, GPR120 is to have limited expression in the it has expression in adipose tissue GPR120 is fatty acid and PubMed Scopus Google A. A. fatty acid as sensors to energy PubMed Scopus Google A. fatty secretion Med. PubMed Scopus Google Scholar). it is well recognized that insulin from adipose and play important in glucose of and insulin effects in PubMed Google we in studies on GPR120 expression and its in adipose GPR120 expression in adipose from several and diabetic GPR120 were in white white and in mice and and rats However, in obese and mice and Zucker fatty GPR120 expression was in adipose of GPR120 in was in rats compared with rats GPR120 expression was in adipose tissue of and diabetic rodents, we to the metabolic that are by the dual agonist in was by from the rats treatment with a dual agonist, a GPR40 selective agonist, as well as in from rats. A of genes was that was by the dual agonist as in of the expression was as by expression in rats GPR120 was to have effect in of mice R. agonist improves insulin resistance and in obese Med. PubMed Scopus Google Scholar). In the was to be in of rats compared with that in rats with the dual agonist for in rats not the of expression in of rats were in the treatment in db/db mice, in expression in was in db/db mice compared with control mice with the combination of GPR40 and GPR120 agonists with the dual agonist a effect to expression in in db/db mice lowering of glucose in with such as and a of expression in in to the dual agonist treatment in rats and db/db mice not expression of key genes such as and was in of rats rats and the expression was by the dual agonist, not by the GPR40 selective agonist, a treatment in rats to GPR120 has a effect on lipolysis in adipose the that GPR120 activation lipolysis in a GPR120 selective agonist and of the of PubMed Scopus Google was to and and were was for this in and studies primary adipocytes it is on GPR120 activation in in has as in Compared with were and of the GPR120 treatment for were not effects of the GPR120 agonist on in the of a in insulin not that GPR120 activation directly we GPR120 activation lipolysis in a of rat white adipocytes were and with with of to with suppressed the of and into in the and of that GPR120 activation lipolysis in rat adipocytes in a a of was as a control in this and demonstrated the robust antilipolytic effect of the of of and in in primary only was that the of lipolysis by is by the in primary adipocytes from GPR120 mice and mice was of by was in adipocytes from mice, the effect was in adipocytes from GPR120 mice that activation of GPR120 to its antilipolytic is a that has to as insulin in obese Zucker fatty its mechanism of action was to of lipolysis in adipocytes of adipose lipolysis by fatty acid 2012; PubMed Scopus Google Scholar). the effect of on lipolysis be by GPR120. adipocytes from the GPR120 mice and mice were with in the of of and with to as a suppressed from and GPR120 adipocytes In of by was only in adipocytes, not from GPR120 adipocytes, that effect on lipolysis is by GPR120 a antilipolytic effect in this is in insulin in Google and fatty acid in diabetes for of insulin PubMed Scopus Google of insulin on and of fatty acid in Google Scholar). we that lipolysis in primary adipocytes from Zucker fatty rats was to insulin in primary adipocytes from rats GPR120 agonist attenuated antilipolytic effect in adipocytes from obese compared with rats a antilipolytic effect in obese rat adipocytes were in the adipocytes from from obese rhesus compared with that from rhesus, and for of for the GPR120 agonist and were in the obese rhesus adipocytes the GPR120 agonist antilipolytic effect in primary adipocytes a GPR120 agonist insulin action in adipocytes, was in the of of insulin in rat primary adipocytes. GPR120 agonist improved the of by that GPR120 agonism enhances insulin action in adipocytes the GPR120 agonist a effect to and in the of insulin the to was of GPR120 and insulin to of lipolysis this to a primary rhesus adipocytes were with insulin in the of of in rhesus adipocytes were to in rat GPR120 agonism enhanced the action of insulin to lipolysis resistance and insulin secretion are for the of T2DM. this for T2DM a is the for insulin especially in of safety with (1.Ciudin A. Hernandez C. Simo R. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.Curr. Top. Med. Chem. 2012; 12: 585-604Crossref PubMed Scopus (28) Google Scholar). In the we the that of novel GPR40 and antidiabetic efficacy to that of GPR40 in of diabetes that are with insulin resistance and insulin of studies was on treatment with the combination of a GPR40 selective agonist and a GPR120 selective agonist in db/db mice, of of agonists when achieved to glucose lowering in db/db mice, and glucose lowering was when the agonists were combination improved the insulin of insulin the to combined GPR40 and GPR120 agonism was to the effect of as a it has recognized that efficacy in db/db the combination of GPR40 and GPR120 in a in db/db mice, could be a GPR40 and GPR120 combination improved glucose and glycemic control that was superior to the effect of GPR40 monotherapy. A single a that was in this a molecule that as a dual agonist for GPR40 and GPR120 represents a medicinal chemistry the have only the for each are and fatty the was that it be to a molecule that could and the studies the of such that was to efficacy was the a of with impairments of insulin secretion and of rats with a dual agonist glycemic control the to single GPR40 and as as the to with the dual agonist was with of of islet and islet morphology, of that GPR40 and GPR120 improves the metabolic compared with GPR40 and that this effect is by in a of insulin by GPR120. that insulin resistance efficacy by insulin secretion is not as this of the of T2DM and to insulin secretion is the to insulin insulin resistance a core not in the of insulin have a a in a the that is as the of insulin secretion and insulin action and that is in T2DM of the PubMed Google Scholar). However, the of insulin secretion and insulin the are important we on novel the studies to that it be medicinal chemistry to that GPR40 and GPR120. effect of a dual agonist on insulin action was in ob/ob mice, a of insulin of insulin sensitivity was demonstrated a with a dual agonist, not with a GPR40 agonist on the glucose in with the clamp, is that the key for improved insulin is of insulin improved insulin action in this was not achieved by a GPR40 selective agonist lowering of glucose to that achieved with dual agonist is that the of GPR120 improved insulin this with R. agonist improves insulin resistance and in obese Med. PubMed Scopus Google it is that is expression of GPR120 in the of GPR120 expression are in adipocytes and A. C. and of expression of the fatty acid PubMed Scopus Google Scholar). postulated that GPR120 mechanism of action to insulin resistance adipose on the mechanism of action of GPR120 in adipose tissue the of potential tissue the that the of GPR120 action is and to a action to lipolysis in adipocytes, as be In the we to a of GPR120 agonism improves insulin sensitivity in diabetic GPR120 was to have effect in adipose tissue GPR120 is fatty acid and PubMed Scopus Google we the expression in adipose with expression of genes such as was in rats and db/db mice compared with treatment with a dual agonist, although glycemic not that was not a of the mechanism to insulin resistance in diabetic for the from the are is that were in the the studies were in db/db and ob/ob mice, as well as are mice, were in the is well recognized that the of in adipose tissue in of and diabetes in and glucose in to PubMed Scopus Google Scholar). GPR120 expression was to be in in the and diabetic expression are with the from adipose tissue from obese in expression of the GPR120 fatty acid is in adipocytes by 2012; PubMed Scopus Google C. A. of on the expression of PubMed Scopus Google Scholar). has that obese GPR120 expression in adipose tissue in C. A. of on the expression of PubMed Scopus Google Scholar). In it has that GPR120 expression was in and in C. A. of PubMed Scopus Google Scholar). that GPR120 has a and effect to lipolysis in primary white adipocytes. In with and of lipolysis by insulin is in Google of insulin on and of fatty acid in Google Scholar). In of lipolysis by insulin in adipocytes from rats and rhesus was GPR120 activation was demonstrated to insulin action on lipolysis in the postulated that this is mechanism by activation of GPR120 in adipose could insulin However, in the hyperinsulinemic-euglycemic in ob/ob mice, the dual agonist treatment not in a in as measured by for the the in and in is not could be that GPR120 activation in the of the and glucose In we only measured to be to insights on the novel GPR120 in adipose tissue in studies to improved insulin action in the as well as of in is that directly that lowering of lipolysis improves glucose and insulin sensitivity in and A. C. C. A. of adipose tissue lipolysis improves glucose and insulin sensitivity of PubMed Scopus Google Scholar). in on antilipolytic effect to demonstrated that control of lipolysis is in with in of and insulin resistance and to in obese rhesus PubMed Scopus Google the studies that to the in were to that GPR120 a effect in primary adipocytes from adipose from rhesus in that GPR120 insulin action on and is with by GPR120 in was by primary adipocytes from of that a GPR120 agonist lipolysis this is a studies with adipocytes, from of weight and of are to this be that is a potential for pharmacological agonism of In it has that a single of of in a in fatty acid by PubMed Google and in clinical studies A. of acid on fatty acid and of glucose in PubMed Google Scholar). is that a recent that has a on metabolic control A. acid to tissue and improves glucose control in obese Zucker PubMed Scopus Google Scholar). In obese Zucker of acid with not with was to lowering and glucose in be of insulin is that GPR120 expression to be a in this is in obese C. A. of on the expression of PubMed Scopus Google Scholar). on the of antilipolytic effect by a GPR120 agonist by with treatment in a is to the of GPR120 agonism as a potential for lowering and insulin In GPR40 and GPR120 dual agonism the of insulin resistance and β-cell and to and glycemic in of T2DM. in that GPR40 and GPR120 dual agonism represents a treatment for T2DM. In the of this that was as a in on the that and to this work was has and and for rhesus adipose tissue and for and and for with the with glucose the obese glucose Zucker diabetic fatty glucose fatty acid glucose type 2 diabetes mellitus white adipose tissue Zucker